9-Hydroxycanthin-6-one
9-Hydroxycanthin-6-one is a β-carboline alkaloid. 9-Hydroxycanthin-6-one can be isolated from the roots of E. longifolia. 9-Hydroxycanthin-6-one inhibits TNF-α-induced activation of the NF-κB pathway. 9-Hydroxycanthin-6-one activates GSK3β independently of CK1α, drives phosphorylation and degradation of β-catenin, and inhibits the Wnt signaling pathway. 9-Hydroxycanthin-6-one exerts selective cytotoxicity against Wnt-dependent colon cancer cells. 9-Hydroxycanthin-6-one can be used in studies related to colon cancer.
For research use only. We do not sell to patients.
- CAS No.: 138544-91-9
- Formula: C14H8N2O2
- Molecular Weight:236.23
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Biological Activity
Description
IC50 & Target
[1]|
GSK3β |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | ED50 |
10 μg/mL
Compound: 9-hydroxycanthin-6-one
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 14575431] |
| Breast carcinoma cell | IC50 |
1.5 μg/mL
Compound: 31
|
Cytotoxicity against human Breast cancer cell
Cytotoxicity against human Breast cancer cell
|
[PMID: 34332400] |
| Calu-3 | CC50 |
>100 μM
Compound: Table 1, R10C2
|
Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
|
[PMID: 36399766] |
| Cancer cell lines | ED50 |
2.6 μg/mL
Compound: 3
|
Cytotoxicity against human breast cancer cells
Cytotoxicity against human breast cancer cells
|
[PMID: 1800638] |
| Cancer cell lines | ED50 |
3.8 μg/mL
Compound: 3
|
Cytotoxicity against human lung cancer cells
Cytotoxicity against human lung cancer cells
|
[PMID: 1800638] |
| Cancer cell lines | ED50 |
4.8 μg/mL
Compound: 3
|
Cytotoxicity against human colon cancer cells
Cytotoxicity against human colon cancer cells
|
[PMID: 1800638] |
| Colon cancer cell line | IC50 |
1.5 μg/mL
Compound: 31
|
Cytotoxicity against human Colon cancer cell line
Cytotoxicity against human Colon cancer cell line
|
[PMID: 34332400] |
| DLD-1 | IC50 |
>40 μM
Compound: 1
|
Cytotoxicity against Wnt-dependent human DLD1 cells assessed as cell viability after 24 hrs by fluorescence assay
Cytotoxicity against Wnt-dependent human DLD1 cells assessed as cell viability after 24 hrs by fluorescence assay
|
[PMID: 25905468] |
| Fibrosarcoma cell line | IC50 |
1.5 μg/mL
Compound: 31
|
Cytotoxicity against human Fibrosarcoma cell line
Cytotoxicity against human Fibrosarcoma cell line
|
[PMID: 34332400] |
| HCT-116 | IC50 |
30 μM
Compound: 1
|
Cytotoxicity against Wnt-dependent human HCT116 cells assessed as cell viability after 24 hrs by fluorescence assay
Cytotoxicity against Wnt-dependent human HCT116 cells assessed as cell viability after 24 hrs by fluorescence assay
|
[PMID: 25905468] |
| HCT-8 | CC50 |
60.88 μM
Compound: Table 1, R10C2
|
Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay
Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay
|
[PMID: 36399766] |
| HEK293 | IC50 |
36.7 μM
Compound: 1
|
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by fluorescence assay
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by fluorescence assay
|
[PMID: 25905468] |
| HEK293 | IC50 |
6.8 μM
Compound: 1
|
Activation of GSK-3beta in HEK293 cells assessed as suppression of TCF/beta-catenin transcriptional activity after 24 hrs by SuperTOPFlash reporter gene assay
Activation of GSK-3beta in HEK293 cells assessed as suppression of TCF/beta-catenin transcriptional activity after 24 hrs by SuperTOPFlash reporter gene assay
|
[PMID: 25905468] |
| HEK-293T | IC50 |
>40 μM
Compound: 1
|
Cytotoxicity against HEK293T cells assessed as cell viability after 24 hrs by fluorescence assay
Cytotoxicity against HEK293T cells assessed as cell viability after 24 hrs by fluorescence assay
|
[PMID: 25905468] |
| HepG2 | CC50 |
>100 μM
Compound: Table 1, R10C2
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
|
[PMID: 36399766] |
| KB | ED50 |
2 μg/mL
Compound: 3
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 1800638] |
| KB | IC50 |
1.5 μg/mL
Compound: 31
|
Cytotoxicity against human Vincristine-resistant KB cells
Cytotoxicity against human Vincristine-resistant KB cells
|
[PMID: 34332400] |
| KB-V1 | ED50 |
>20 μg/mL
Compound: 3
|
Cytotoxicity against human KBV1 cells
Cytotoxicity against human KBV1 cells
|
[PMID: 1800638] |
| Lung cancer cell line | IC50 |
1.5 μg/mL
Compound: 31
|
Cytotoxicity against human Lung cancer cell line
Cytotoxicity against human Lung cancer cell line
|
[PMID: 34332400] |
| MCF7 | ED50 |
19.6 μg/mL
Compound: 9-hydroxycanthin-6-one
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 14575431] |
| Melanoma cell | ED50 |
5.4 μg/mL
Compound: 3
|
Cytotoxicity against human melanoma cells
Cytotoxicity against human melanoma cells
|
[PMID: 1800638] |
| Melanoma cell line | IC50 |
1.5 μg/mL
Compound: 31
|
Cytotoxicity against human Melanoma cell line
Cytotoxicity against human Melanoma cell line
|
[PMID: 34332400] |
| MRC5 | CC50 |
>100 μM
Compound: Table 1, R10C2
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
|
[PMID: 36399766] |
| P388 | ED50 |
1.5 μg/mL
Compound: 3
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 1800638] |
| RKO | IC50 |
>40 μM
Compound: 1
|
Cytotoxicity against Wnt-independent human RKO cells assessed as cell viability after 24 hrs by fluorescence assay
Cytotoxicity against Wnt-independent human RKO cells assessed as cell viability after 24 hrs by fluorescence assay
|
[PMID: 25905468] |
| SW480 | IC50 |
17.4 μM
Compound: 1
|
Cytotoxicity against Wnt-independent human SW480 cells assessed as cell viability after 24 hrs by fluorescence assay
Cytotoxicity against Wnt-independent human SW480 cells assessed as cell viability after 24 hrs by fluorescence assay
|
[PMID: 25905468] |
| Vero | CC50 |
>100 μM
Compound: Table 1, R10C2
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay
|
[PMID: 36399766] |
In Vitro
9-Hydroxycanthin-6-one (3.8-30 μM; 30 min pretreatment, 4 h TNF-α stimulation) potently inhibits TNF-α-induced NF-κB activation in HEK-293/NF-κB-luc cells with an IC50 of 3.8 μM, and exhibits no cytotoxicity at 30 μM[1].
9-Hydroxycanthin-6-one (5-20 μM; 24 h) potently and selectively inhibits TCF/β-catenin transcriptional activity in STF/293 cells with an IC50 of 6.8 μM, while preserving high cell viability[2].
9-Hydroxycanthin-6-one (24 h) selectively inhibits the viability of Wnt-dependent human colon cancer cells (SW480, HCT116) with IC50 values of 17.4 μM and 30.0 μM, respectively, while sparing Wnt-independent and noncancer cell lines[2].
9-Hydroxycanthin-6-one (10-30 μM; 24 h) dose-dependently reduces total β-catenin levels (in whole cell, cytosolic, and nuclear fractions) and increases β-catenin phosphorylation at GSK3β target sites (Ser33/Ser37/Thr41) in SW480 cells, without altering CK1α-mediated β-catenin phosphorylation or total GSK3β/CK1α levels[2].
9-Hydroxycanthin-6-one (30 μM; 24 h post-siRNA transfection) inhibits Wnt signaling in SW480 cells through GSK3β activation independent of CK1α, as it reduces β-catenin and increases GSK3β-mediated β-catenin phosphorylation even when CK1α is knocked down[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SW480 cells
-
Concentration:10, 20, 30 μM
-
Incubation Time:24 h
-
Result:Dose-dependently decreased total β-catenin protein levels in whole cellular, cytosolic, and nuclear fractions.
Dose-dependently increased phosphorylated β-catenin at Ser33/Ser37/Thr41 (GSK3β phosphorylation sites).
Had no effect on phosphorylated β-catenin at Ser45 (CK1α phosphorylation site) or total GSK3β/CK1α protein levels.
-
Cell Line:SW480 cells
-
Concentration:30 μM
-
Incubation Time:24 h (post-siRNA transfection)
-
Result:Decreased β-catenin levels and increased phosphorylated β-catenin at Ser33/Ser37/Thr41 in cells transfected with control siRNA.
Attenuated reduction in β-catenin levels in cells transfected with GSK3β siRNA.
Decreased phosphorylated GSK3β at Ser9 (inactive form) protein levels.\nDecreased β-catenin levels and increased phosphorylated β-catenin at Ser33/Ser37/Thr41 in both control siRNA-transfected and CK1α siRNA-transfected cells.
Decreased phosphorylated GSK3β at Ser9 levels in CK1α siRNA-transfected cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:TOPdGFP transgenic strain; wild-type AB strain (embryos)[2]
-
Dosage:300 μM (TOPdGFP activity, Wnt target gene expression, pigment cell assessment); 100 μM (eyeless phenotype rescue)
-
Administration:immersion in E3 medium; 10 hpf to 24 hpf (TOPdGFP activity); immersion in E3 medium; 4 hpf to 24 hpf (Wnt target gene expression); immersion in E3 medium; 4 hpf to 30 hpf (pigment cell assessment); immersion in E3 medium; 4 hpf to 30 hpf, co-administered with 0.5 μM BIO (eyeless phenotype rescue)
-
Result:Reduced TOPdGFP activity in the midbrain tectum of 24 hpf embryos without inducing excess cell death (control MO group: 100% activity, n=10; p53 MO group: 100% activity, n=10).
Reduced zic2a expression in the midbrain tectum of 24 hpf embryos (control MO group: 55% expression, n=6; p53 MO group: 54% expression, n=7).
Reduced mitf expression in neural-crest cells of 24 hpf embryos (control MO group: 50% expression, n=7; p53 MO group: 60% expression, n=9).
Reduced the number of pigment cells in the tails of 30 hpf embryos (100% reduction, n=10).
Rescued the eyeless phenotype induced by 0.5 μM BIO in 30 hpf embryos, with 46% showing fully rescued eyes (n=6) and 54% showing slightly rescued eyes (n=7).
Chemical Information
-
CAS No. 138544-91-9
-
Appearance Solid
-
Molecular Weight 236.23
-
Formula C14H8N2O2
-
Color Light yellow to yellow
-
SMILES
O=C1N2C3=C(N=CC=C3C4=C2C=C(O)C=C4)C=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1].
Thi Van Anh Tran, et al. NF-κB inhibitors from Eurycoma longifolia. J Nat Prod. 2014 Mar 28;77(3):483-8.
[Content Brief]
[2]. Ohishi K, et al. 9-Hydroxycanthin-6-one, a β-Carboline Alkaloid from Eurycoma longifolia, Is the First Wnt Signal Inhibitor through Activation of Glycogen Synthase Kinase 3β without Depending on Casein Kinase 1α. J Nat Prod. 2015 May 22;78(5):1139-46. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)